Scholarlink

Background <p>Accurate prognostic prediction in pancreatic cancer is of paramount clinical importance for patient management. However, a reliable and non-invasive method for preoperatively predicting overall survival (OS) remains a significant unmet need. We aim to evaluate the utility of pre-operative <sup>18</sup>F-fluorodeoxyglucose (<sup>18</sup>F-FDG) positron emission tomography (PET)/ computed tomography (CT)-derived signatures in predicting OS in patients with pancreatic ductal adenocarcinoma (PDAC).</p> Results <p>This study included 109 patients (70 males, 39 females). Over a median follow-up period of 28&#xa0;months (range, 1-64&#xa0;months), 68 patients (62.4%) died (median OS, 15&#xa0;months). As stated above, a series of models was established using selected radiomics features and clinical factors. In the test set, the C-index of the clinical, CT-based, PET-based, PET/CT-based, and integrated model were 0.586, 0.724, 0.730, 0.730, and 0.743, respectively. The PET-based model (<i>P</i>&#xa0;=&#xa0;0.027) significantly outperformed the clinical model, unlike the CT-based model (<i>P</i>&#xa0;=&#xa0;0.057); further feature integration did not improve performance. </p> Conclusion <p>In this study, <sup>18</sup>F-FDG PET/CT radiomics features showed promise in predicting OS in patients with PDAC, suggesting potential as a tool for personalized management and warranting large-scale studies to confirm its applicability in clinical practice.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Predicting overall survival in pancreatic ductal adenocarcinoma using 18F-FDG PET/CT radiomics: a two-center study​

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月24日

查看全文
  • Yang Xu,
  • Yunmei Shi,
  • Tao Jiang,
  • Qingxia Wu,
  • Ren Lang,
  • Yuetao Wang,
  • Min-Fu Yang

摘要

Background

Accurate prognostic prediction in pancreatic cancer is of paramount clinical importance for patient management. However, a reliable and non-invasive method for preoperatively predicting overall survival (OS) remains a significant unmet need. We aim to evaluate the utility of pre-operative 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/ computed tomography (CT)-derived signatures in predicting OS in patients with pancreatic ductal adenocarcinoma (PDAC).

Results

This study included 109 patients (70 males, 39 females). Over a median follow-up period of 28 months (range, 1-64 months), 68 patients (62.4%) died (median OS, 15 months). As stated above, a series of models was established using selected radiomics features and clinical factors. In the test set, the C-index of the clinical, CT-based, PET-based, PET/CT-based, and integrated model were 0.586, 0.724, 0.730, 0.730, and 0.743, respectively. The PET-based model (P = 0.027) significantly outperformed the clinical model, unlike the CT-based model (P = 0.057); further feature integration did not improve performance.

Conclusion

In this study, 18F-FDG PET/CT radiomics features showed promise in predicting OS in patients with PDAC, suggesting potential as a tool for personalized management and warranting large-scale studies to confirm its applicability in clinical practice.